文献速递核素与放射性配体治疗肿瘤 PET/CT

利用多模态影像预测胃肠胰神经内分泌肿瘤患者177Lu-DOTATATE PRRT的疗效:前瞻性II期LUMEN研究结果

Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
PubMed 文献 · J Nucl Med · 2024-02-01

该前瞻性II期研究纳入37例进展期胃肠胰神经内分泌肿瘤患者,接受4个周期7.4 GBq 177Lu-DOTATATE治疗,评估多模态影像参数与肿瘤剂量学对无进展生存期(PFS)和客观缓解的预测价值。中位PFS为28个月,11例(30%)达部分缓解;所有靶病灶最小C1肿瘤吸收剂量达35 Gy的患者PFS显著更长(48.1 vs 26.2个月;HR 0.37;95%CI 0.17-0.82;P=0.02),C1后SSTR肿瘤体积下降超过10%的患者PFS亦更长(51.3 vs 22.8个月;HR 0.35;95%CI 0.16-0.75;P=0.003)。

要点

  • 所有靶病灶最小C1肿瘤吸收剂量达35 Gy者PFS显著更长(48.1 vs 26.2个月;HR 0.37;P=0.02)。
  • C1后SSTR肿瘤体积下降超过10%者PFS更长(51.3 vs 22.8个月;HR 0.35;P=0.003)。
  • 其他剂量学或影像参数与病灶或患者结局无统计学关联证据。

核心结论

  • C1时最小肿瘤吸收剂量可预测接受PRRT的GEP-NET患者结局,为个性化剂量学指导的治疗策略提供依据。
  • C1后SSTR肿瘤体积下降可用于早期疗效评估,作为PRRT结局的预测指标。

研究设计与样本

  • 前瞻性II期LUMEN研究,纳入进展期GEP-NET患者,治疗为4个周期7.4 GBq 177Lu-DOTATATE。
  • 在每次注射后约10周对每例患者最多5个靶病灶行68Ga-DOTATATE PET/CT、18F-FDG PET/CT和扩散加权MRI测量影像参数。
  • 每个周期用SPECT/CT在3个时间点进行肿瘤剂量学测定,基线影像参数、C1后相对变化及C1肿瘤吸收剂量与病灶形态学结局进行相关性分析。
  • 将每例患者影像参数平均值及C1肿瘤吸收剂量的最小值、最大值和均值与PFS和最佳客观缓解(RECIST 1.1)进行关联检验。

主要发现

  • 37例患者中位PFS为28个月,11例(30%)达部分缓解(RECIST 1.1)。
  • 中位随访57个月,84个可形态学评估病灶的中位至病灶进展时间未达到,仅12个(14%)进展(较基线增大≥20%)。
  • 所有靶病灶最小C1剂量达35 Gy的患者PFS显著更长(48.1 vs 26.2个月;HR 0.37;95%CI 0.17-0.82;P=0.02)。
  • C1后SSTR肿瘤体积下降超过10%的患者PFS更长(51.3 vs 22.8个月;HR 0.35;95%CI 0.16-0.75;P=0.003)。
  • 其他剂量学或影像参数与病灶或患者结局无统计学关联证据。

关键数值与推荐

  • 所有靶病灶最小C1肿瘤吸收剂量阈值35 Gy:达此阈值者PFS 48.1个月 vs 未达者26.2个月(HR 0.37;95%CI 0.17-0.82;P=0.02)。
  • C1后SSTR肿瘤体积下降超过10%:下降超过10%者PFS 51.3个月 vs 未超过者22.8个月(HR 0.35;95%CI 0.16-0.75;P=0.003)。
  • 客观缓解按RECIST 1.1评估,37例中11例(30%)达部分缓解。
  • 病灶形态学进展定义为较基线增大≥20%,84个可评估病灶中12个(14%)进展。

临床怎么用

  • 作者认为C1时最小肿瘤吸收剂量可预测接受PRRT的GEP-NET患者结局,为个性化剂量学指导的治疗策略提供依据。
  • 作者认为C1后SSTR肿瘤体积下降可用于早期疗效评估,作为PRRT结局的预测指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to predict the outcome of peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine tumor (GEP-NET) lesions and patients. Methods: This prospective study included patients with progressive GEP-NETs. Treatment consisted of 4 cycles of 7.4 GBq of 177Lu-DOTATATE. Imaging parameters were measured on 68Ga-DOTATATE PET/CT (SUVmax/mean, somatostatin receptor [SSTR] tumor volume [TV], total lesion SSTR expression, and tumor-to-blood and tumor-to-spleen ratios), 18F-FDG PET/CT (SUVmax/mean, metabolically active TV, and total lesion glycolysis), and diffusion-weighted MRI (apparent diffusion coefficient) in a maximum of 5 target lesions per patient at approximately 10 wk after each injection. Tumor dosimetry was performed using SPECT/CT at 3 time points for every cycle. Baseline imaging parameters, their relative changes after PRRT cycle 1 (C1), and the tumor-absorbed dose at C1 were correlated with lesion morphologic outcome. The average values of the imaging parameters and the minimal, maximal, and mean C1 tumor-absorbed dose in each patient were tested for association with progression-free survival (PFS) and best objective response (RECIST 1.1). Results: In the 37 patients, the median PFS was 28 mo. Eleven of the 37 (30%) achieved a partial response (RECIST 1.1). After a median follow-up of 57 mo, the median time to lesion progression had not been reached in 84 morphologically evaluable lesions, with only 12 (14%) progressing (size increase ≥ 20% from baseline). Patients receiving a minimal C1 dose of 35 Gy in all target lesions exhibited a significantly longer PFS (48.1 vs. 26.2 mo; hazard ratio, 0.37; 95% CI, 0.17-0.82; P = 0.02). Volumetric 68Ga-DOTATATE PET parameters correlated with lesion and patient outcome: patients with an SSTR TV decrease of more than 10% after C1 had a longer PFS (51.3 vs. 22.8 mo; hazard ratio, 0.35; 95% CI, 0.16-0.75; P = 0.003). There was no statistical evidence of an association between other dosimetric or imaging parameters and the lesion or patient outcome. Conclusion: Minimal tumor-absorbed dose at C1 is predictive of outcome in patients with GEP-NETs treated with PRRT, providing a basis for personalized dosimetry-guided treatment strategies. An SSTR TV decrease after C1 could be used for early therapy response assessment as a predictor of PRRT outcome.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mileva M, Marin G, Levillain H, et al. Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. J Nucl Med. 2024. PMID: 38164576. doi:10.2967/jnumed.123.265987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。